

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY PANAMA	2. DATE OF BIRTH			2a. AGE 67 Years	3. SEX Male	3a. WEIGHT 61.00 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
		Day	Month	Year			Day	Month	Year		
			PRIVACY					APR	2025		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)
Low potassium [Potassium low]

Case Description: This patient support program case related to protocol number (IC4-06593-001-PAN) was received from patient in PANAMA.

The patient was a 67-year-old male (Height: 177 cm and Weight: 61 kg) with a medical history of Hypertension since unknown date in 2005, treated with PERINDOPRIL ARG 5 / INDA 1.25 / AMLO 5-F36 (1DF daily, orally) since unknown date in 2023 to unknown date in APR-2025, Cholesterol problems since birth, treated with Rosuvastatin (20 mg daily,

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) PERINDOPRIL ARG 5 / INDA 1.25 / AMLO 5-F36 (PERINDOPRIL ARGinine 5 mg, INDAPAMIDE 1.25 mg, (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) #1) 1 DF, qd	16. ROUTE(S) OF ADMINISTRATION #1) Oral use	
17. INDICATION(S) FOR USE #1) Hypertension (Hypertension)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 2023 / APR-2025	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) Rosuvastatin (Rosuvastatin) ; 2015 / Unknown		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates Unknown to Ongoing	Type of History / Notes Historical Condition	Description Blood cholesterol abnormal (Blood cholesterol abnormal)
2005 to Ongoing	Historical Condition	Hypertension (Hypertension)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER SERVIER CENTRO AMERICA Y CARIBE PANAMA		26. REMARKS Patient ID: 64949 Study ID: IC4-06593-001-PAN*
	24b. MFR CONTROL NO. S25010249	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 12-JUL-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 25-JUL-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

orally) since unknown date in 2015.

No other concomitant treatment was reported if any.

On an unknown date in APR-2025, the patient experienced Low potassium.

Patient doctor told that one of the components of TRIPLIXAM (it was not known which one) was lowering his potassium, so he changed it to COVERAM 5/5MG.

Treatment for the reaction (Low potassium) was unknown.

On an unknown date in APR-2025, doctor changed TRIPLIXAM 5/1.25/5MG to COVERAM 5/5MG.

Action taken regarding PERINDOPRIL ARG 5 / INDA 1.25 / AMLO 5-F36 was drug withdrawn.
Outcome: Recovered.

The seriousness assessment as per reporter was non-serious.

The causality assessment as per reporter was related.

Consent to contact the doctor was not obtained.

Case Comment: Blood potassium decreased is listed as per RSI of PERINDOPRIL ARG 5 / INDA 1.25 / AMLO 5-F36. Considering the known side effect, positive dechallenge with missing information (definitive therapy and event dates, investigations) the causal role is probable.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Blood potassium		
		Low		

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) PERINDOPRIL ARG 5 / INDA 1.25 / AMLO 5-F36 (PERINDOPRIL ARGinine 5 mg, INDAPAMIDE 1.25 mg, AMLODIPINE 5 mg) Tablet, 5/1.25/5 mg; Regimen #1	1 DF, qd; Oral use	Hypertension (Hypertension)	2023 / APR-2025; Unknown